SARS-CoV-2 neutralizing antibody (Nab) responses;SARS-CoV-2-specific T helper 1 (Th1) cell-mediated immune (CMI) responses;SARS-CoV-2-specific T helper 2 (Th2) CMI responses;The incidences and severity of the following solicited AEs;The incidences of serious AEs (SAEs), medically attended AEs (MAAEs), AEs leading to withdrawal, AEs of special interest (AESIs), and deaths;The incidences, severity, and investigator-assessed causality of immediate adverse events (AEs);The incidences, severity, and investigator-assessed causality of unsolicited AEs

SARS-CoV-2 neutralizing antibody (Nab) responses;SARS-CoV-2-specific T helper 1 (Th1) cell-mediated immune (CMI) responses;SARS-CoV-2-specific T helper 2 (Th2) CMI responses;The incidences and severity of the following solicited AEs;The incidences of serious AEs (SAEs), medically attended AEs (MAAEs), AEs leading to withdrawal, AEs of special interest (AESIs), and deaths;The incidences, severity, and investigator-assessed causality of immediate adverse events (AEs);The incidences, severity, and investigator-assessed causality of unsolicited AEs